Evidence map›Paper›PMID 36550350›Full record

ArticleHepatology international2023

Whole-exome sequencing identifies a set of genes as markers of hepatocellular carcinoma early recurrence.

Huizhong Shi, Wenwen Zhang, Bingyang Hu, Yafei Wang, Ze Zhang, Ying Sun, Guankun Mao, Chonghui Li, Shichun Lu

Abstract read
PubMed Publisher
In one paragraph

Article in Hepatology international, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.2field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Multiple roles and mechanisms of MUC6 in cancer (Review).International journal of molecular medicine · 2025
    Review
  2. Article
  3. Diagnostic model using LI-RADS v2018 for predicting early recurrence of microvascular invasion-negative solitary hepatocellular carcinoma.Cancer imaging : the official publication of the International Cancer Imaging Society · 2025
    Article
  4. Article
  5. Sequencing Analysis ofCurrent issues in molecular biology · 2023
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Huizhong ShiMedical School of China PLA, Beijing, China.
Wenwen ZhangThe First Medical Centre, Chinese PLA General Hospital, Beijing, 100853, China.
Bingyang HuThe First Medical Centre, Chinese PLA General Hospital, Beijing, 100853, China.
Yafei WangThe First Medical Centre, Chinese PLA General Hospital, Beijing, 100853, China.
Ze ZhangMedical School of China PLA, Beijing, China.
Ying SunGenomiCare Biotechnology (Shanghai) Co., Ltd., Shanghai, China.
Guankun MaoThe First Medical Centre, Chinese PLA General Hospital, Beijing, 100853, China.
Chonghui LiThe First Medical Centre, Chinese PLA General Hospital, Beijing, 100853, China.
Shichun LuThe First Medical Centre, Chinese PLA General Hospital, Beijing, 100853, China. Lusc_301@163.com.
Second Military Medical University · CNChinese PLA General Hospital · CNEastern Hepatobiliary Surgery Hospital · CNGenomiCare (China) · CN

Funding

National Natural Science Foundation of China 81670590
6 · The paper itself

Abstract

backgroundHepatocellular carcinoma (HCC) is characterized by a high recurrence rate and poor prognosis. In recent years, the therapeutic regimen of programmed cell death protein 1 (PD-1) antibody combined with multi-targeted tyrosine kinase inhibitors (mTKIs) has achieved better results in the clinical application of hepatocellular carcinoma. Whole-exome sequencing can reflect the mutational characteristics of patients' exons and guide the clinical selection of molecular targeting drugs more accurately, which is in line with the concept of precision medicine.

methodsWe performed exome sequencing on 63 patients with HCC treated with radical surgery at our hospital and collected their clinical indexes and postoperative follow-up data. Using machine learning, a prediction model for recurrence within 1 year was constructed and the model was presented in a nomogram. Patients treated with PD-1 antibodies in combination with mTKIs after relapse were grouped by prognosis, and the valuable mutated genes were screened according to whole-exome sequencing data. The tumor tissue immune cells were analyzed using the UCSC Xena database. The expressions of target proteins were verified by Polymerase Chain Reaction (PCR) and Immunohistochemistry (IHC), respectively, on commercial HCC cell lines and pathological specimens of hepatocellular carcinoma collected clinically.

resultsThe proportion of patients who relapsed within a year was 41% and the prognosis of those patients was poor. The characteristic exon mutation profile with a high frequency of variants in multiple mucin genes was present in Chinese HCC patients. Multiple nidi and 30 exon variants were brought into the prediction model with an area under the curve (AUC) = 0.94. MUC6 gene mutation was obvious in patients with an early recurrence, and MUC3A and MUC4 gene mutations were evident in patients with poorer responses to PD-1 antibodies combined with mTKIs. Those three mucins were negatively correlated with immune infiltrating cells.

conclusionsWe depicted the exon characteristics of hepatocellular carcinoma in the Chinese population and established a predictive model for recurrence within 1 year after radical surgical treatment. Moreover, we found that mucins were worthy targets of hepatocellular carcinoma.

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsChronic DiseaseExome SequencingHumansNeoplasm Recurrence, LocalProgrammed Cell Death 1 ReceptorProgrammed Cell Death 1 ReceptorEarly recurrenceHepatocellular carcinomaImmunotherapyMachine learningPrediction modelTargeted therapyWhole-exome sequencing

Identifiers

PMID36550350
OpenAlexW4312114664

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.